A randomized, open label study evaluating the effect on renal function of intravenous Bonviva [ibandronic acid] given by injection or infusion, compared with oral alendronate [alendronic acid], in postmenopausal women with osteoporosis at high risk for renal disease.

Trial Profile

A randomized, open label study evaluating the effect on renal function of intravenous Bonviva [ibandronic acid] given by injection or infusion, compared with oral alendronate [alendronic acid], in postmenopausal women with osteoporosis at high risk for renal disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2011

At a glance

  • Drugs Alendronic acid; Ibandronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions
  • Acronyms DIVINE
  • Sponsors Roche
  • Most Recent Events

    • 01 Dec 2011 Tolerability results published in Bone.
    • 16 Apr 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 18 Dec 2009 Planned number of patients changed from 855 to 801 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top